Latest Healthcare News

Epsilon Healthcare Limited is poised to return to ASX trading on 19 December 2025 after satisfying the exchange's conditions for reinstatement.

PeopleIN Limited has announced the sale of its Health and Community brands to Healthcare Australia for $20.25 million, unlocking capital to fuel growth in infrastructure, defence, and agriculture sectors.

PeopleIN Limited has sold its health and aged care staffing arms for $20.25 million, aiming to eliminate net debt and accelerate growth in defence, engineering, and trades sectors.

Epsilon Healthcare Limited has unveiled a comprehensive pre-reinstatement disclosure, highlighting improved financial health and a strategic growth plan focused on operational stability and expansion.

Arena REIT reports a $61 million uplift in portfolio valuation for H1 FY2026, driven by strong investor interest in early learning centres and a tightening yield environment. The company reaffirms its FY2026 distribution guidance, signaling confidence in its growth trajectory.

Arena REIT has declared a quarterly distribution of 4.8125 cents per security, aligning with its FY26 guidance, while offering a discounted Dividend Reinvestment Plan to investors.

Epsilon Healthcare has bolstered its working capital through a $2 million loan from its Managing Director and deferred director-related payments until 2027, signaling confidence amid liquidity management efforts.

Micro-X Limited has secured $6 million through a share placement to accelerate commercialisation of its innovative medical imaging technologies, with strategic partner Billion Prima increasing its stake to 8.5%. The capital raise supports key clinical trials and product development milestones.

Cleo Diagnostics has raised $5 million to support the U.S. commercial launch of its Pre-Surgical Ovarian Cancer Test and accelerate development of a mass screening test, signaling strong investor confidence in its technology.

Orthocell has reached a significant milestone with 100 units of its nerve repair product Remplir™ sold in the US, signaling accelerating adoption in a $1.6 billion market. The company’s strategic medical education and distributor network are driving momentum ahead of further hospital approvals.

Receivers and administrators have been appointed to 54 pharmacies within the Infinity Retail Pharmacy Group, catching Paragon Care off guard despite ongoing debt restructuring talks. The company pledges to support an orderly resolution to maximise creditor returns.

Memphasys Limited’s partner International Technical Legacy has placed an early order for 500 Felix™ cartridges ahead of anticipated CE Mark approval, signalling strong clinic demand and validating the company’s direct-selling strategy in the Middle East.